Anti-glycation agent, and method for producing Anti-glycation agent
The combination of cyclodextrin and NMN in an anti-glycation agent effectively addresses the limitations of NMN alone by enhancing its anti-glycation effect, improving healthy lifespan under sugar load conditions.
Patent Information
- Application Number
- JP2023075895
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-01
- Publication Date
- 2024-11-14
AI Technical Summary
Existing anti-glycation agents, such as those containing nicotinamide mononucleotide (NMN) alone, do not effectively address the issue of advanced glycation end products (AGEs) that contribute to age-related diseases and diabetic complications.
Combining cyclodextrin (CyD) with NMN to form an anti-glycation agent, which enhances the anti-glycation effect beyond what NMN can achieve alone.
The CyD-NMN combination significantly improves healthy lifespan under sugar load conditions by reducing the population of unhealthy or short-lived organisms, demonstrating a robust anti-glycation property.
Smart Images

Figure 2024160659000001 
Figure 2024160659000002
Abstract
Description
[Technical field]
[0001] The present invention relates to an anti-glycation agent and a method for producing an anti-glycation agent. [Background technology]
[0002] Glycation is a series of chemical reactions that begins with the nonenzymatic binding of a carbonyl group of a reducing sugar to an amino group of a protein or amino acid, resulting in the production of advanced glycation endproducts (AGEs). AGEs produced by glycation in the body cause various age-related diseases, diabetic complications, inflammation, etc. Diabetic complications include, for example, diabetic nephropathy and myocardial infarction, which can have a negative impact on healthy life expectancy.
[0003] Meanwhile, in recent years, various studies have shown that taking nicotinamide mononucleotide (hereinafter sometimes referred to as "NMN") can improve degenerative changes caused by aging. For this reason, NMN has been attracting attention as an additive ingredient for food and beverages, medicines, cosmetics, and the like. For example, Patent Document 1 discloses a dietary supplement that contains NMN as an active ingredient. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] JP 2018-002604 A Summary of the Invention [Problem to be solved by the invention]
[0005] The present inventors have discovered that the NMN in the coexistence of cyclodextrin (hereinafter sometimes referred to as "CyD") has a superior anti-glycation effect compared to the use of NMN alone.
[0006] Therefore, an object of the present invention is to provide an anti-glycation agent having an excellent anti-glycation effect, and a method for producing the anti-glycation agent. [Means for solving the problem]
[0007] To achieve the above object, the anti-glycation agent of the present invention includes cyclodextrin and nicotinamide mononucleotide.
[0008] The method for producing an anti-glycation agent of the present invention includes a mixing step of mixing cyclodextrin and nicotinamide mononucleotide. Effect of the Invention
[0009] According to the present invention, an anti-glycation effect can be achieved. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 is a graph showing the health impact index (qHaS) per anti-glycation agent or agents administered. [Diagram 2] FIG. 2 is a graph showing the change in healthy and unhealthy nematode populations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following description in any way.
[0012] [1. Anti-glycation agents] First, the anti-glycation agent of the present invention will be described.
[0013] In the present invention, unless otherwise specified, "anti-glycation" refers to qualitatively improving the healthy lifespan under glucose loading conditions. In addition, in the present invention, unless otherwise specified, "glucose loading conditions" refers to conditions in which glucose concentrations are high, for example, In vitro So, glucose-containing medium, In vivoExamples of such conditions include metabolic syndrome, prediabetes, type I diabetes, and type II diabetes. In the present invention, the term "healthy lifespan" refers to the period during which one can live without being restricted in daily life due to health problems, unless otherwise specified. For example, the health lifespan of a nematode, which will be described later, can be an indirect indicator of the health lifespan of a human. In the present invention, "qualitatively improving the health lifespan under sugar loading conditions" refers to improving the health lifespan under the sugar loading conditions so that the health lifespan of a nematode, which will be described later, or the health lifespan of a human calculated indirectly from the health lifespan of a nematode, is not unhealthy or short-lived.
[0014] As described above, the anti-glycation agent of the present invention includes cyclodextrin and nicotinamide mononucleotide.
[0015] The CyD may be, for example, one containing at least one of α-CyD, β-CyD, γ-CyD, δ-CyD, ε-CyD, ζ-CyD, η-CyD, and θ-CyD. From the viewpoint of availability, it is preferable to contain at least one of α-CyD, β-CyD, and γ-CyD, and from the viewpoint of solubility in water, it is more preferable to contain α-CyD. The CyD may also be a derivative of the CyD or a salt thereof.
[0016] The CyD derivative is not particularly limited, and examples thereof include alkylated derivatives, hydroxyalkylated derivatives, alkoxyalkylated derivatives, acetylated derivatives, quaternary ammonium salt derivatives, carboxyalkylated derivatives, maltosylated derivatives, and glucosylated derivatives.
[0017] The salt of CyD is not particularly limited, and examples thereof include acid addition salts and base addition salts. Examples of the acid addition salts include salts having an ion of an inorganic acid or an organic acid. Examples of the inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Examples of the organic acid include acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acid, aromatic sulfuric acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acid, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiary butylacetic acid, trimethylacetic acid, etc. Examples of the base addition salt include salts having an ion of an inorganic base or an organic base. Examples of the inorganic base include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide, calcium hydroxide, etc. Examples of the organic base include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.
[0018] The CyD may be prepared by any method. For example, a purified CyD artificially synthesized by a method of producing CyD from amylopectin of starch through a reaction with cyclodextrin glycosyltransferase may be used. The cyclodextrin glycosyltransferase may be produced, for example, by culturing a microorganism that produces the cyclodextrin glycosyltransferase in a culture solution and extracting the cyclodextrin glycosyltransferase from the culture solution. Examples of the microorganism that produces the cyclodextrin glycosyltransferase include bacteria of the genus Bacillus. Examples of the starch that can be used include potato, corn, waxy corn, and wheat. Commercially available purified CyD may also be used.
[0019] The NMN may be, for example, at least one of α-NMN and β-NMN, and preferably contains β-NMN. The NMN may also be a derivative of NMN or a salt thereof.
[0020] The NMN derivative is not particularly limited, and may be, for example, pharma- ceutical acceptable. In the present invention, "pharma-ceutical acceptable" refers to not causing any adverse reaction, such as an allergic reaction, when administered to an animal.
[0021] The salt of NMN is not particularly limited, and examples thereof include acid addition salts and base addition salts. Examples of the acid addition salts include salts having an ion of an inorganic acid or an organic acid. Examples of the inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Examples of the organic acid include acetic acid, aliphatic mono- and dicarboxylic acids, aliphatic sulfuric acid, aromatic sulfuric acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hexanoic acid, hydroxynaphthoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, phenyl-substituted alkanoic acid, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, tartaric acid, tertiary butylacetic acid, trimethylacetic acid, etc. Examples of the base addition salt include salts having an ion of an inorganic base or an organic base. Examples of the inorganic base include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide, calcium hydroxide, etc. Examples of the organic base include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.
[0022] The NMN may be prepared by any method. For example, NMN that has been artificially synthesized by chemical synthesis, enzymatic methods, fermentation, or the like and then purified may be used. In addition, since NMN is a component that is widely present in living organisms, NMN obtained by extraction and purification from natural raw materials such as animals, plants, and microorganisms may also be used. Commercially available purified NMN may also be used.
[0023] The molar concentration of NMN contained in the anti-glycation agent of the present invention may be, for example, 1.5 mM or more, 2 mM or more, 3 mM or more, 4 mM or more, or 5 mM or more, and may be 20 mM or less, 15 mM or less, 10 mM or less, 8 mM or less, or 6 mM or less.
[0024] The anti-glycation agent of the present invention may be, for example, for use in a solid composition or a liquid composition. The term "solid composition" refers to a composition that is solid at room temperature. The term "liquid composition" refers to a composition that is liquid at room temperature.
[0025] The anti-glycation agent of the present invention may be for use in, for example, beverages, foods, supplements, general foods, health functional foods, foods for special uses, animal feed, pharmaceuticals, or quasi-drugs.
[0026] Although there is no administrative definition of the supplement in Japan, it is, for example, a product in the form of a tablet or capsule in which a specific ingredient is condensed, and examples of the product include beverages, food, general foods, health functional foods, foods for special uses, etc. The supplement may include, for example, those defined as dietary supplements in the United States and those defined as food supplements in Europe.
[0027] The general foods are, for example, those defined by the standards for nutritional ingredient labeling in the food labeling system related to nutrition and health functions, and are so-called health foods. Examples of the general foods include nutritional supplements, dietary supplements, and nutritionally adjusted foods.
[0028] Examples of the health functional foods include functional foods, nutrient functional foods, and foods for specified health uses, which are defined by the standards for nutritional component labeling in the food labeling system regarding nutrition and health functions.
[0029] Examples of the special dietary foods include foods for specified health uses, foods for the sick, powdered milk for pregnant women and nursing mothers, infant formula, foods for people with difficulty swallowing, etc., as defined by the standards for nutritional composition labeling in the food labeling system for nutrition and health functions.
[0030] When the composition of the present invention is provided as the beverage, food, supplement, general food, health functional food, or special purpose food, it may be in the form of, for example, tablets, capsules, powders, granules, drinks (including solutions and suspensions), etc. It may also be provided for consumption in a state of being mixed with various foods and beverages, for example, in the form of soft drinks, tea drinks, seasonings, processed foods, desserts, confectioneries (e.g., gums, candies, jellies), dairy products (e.g., yogurt, lactic acid bacteria drinks, etc.).
[0031] When the composition of the present invention is provided as animal feed, for example, it may be ingested by animals as is, or may be mixed with other solid feed or drinking water and then ingested by animals.
[0032] When the composition of the present invention is provided as a drug or quasi-drug, it may be, for example, an oral preparation that is orally ingested, an external preparation that is applied to a target site, or an injectable preparation that is administered subcutaneously, intravenously, intramuscularly, intraperitoneally, etc.
[0033] When the pharmaceutical or quasi-drug of the composition of the present invention is an oral preparation, its form may be, for example, powder, granule, tablet, liquid, gel, paste, capsule such as hard capsule or soft capsule, caplet, tablet, gel, jelly, gummy, wafer, biscuit, cookie, cake, chewable, syrup, stick, etc. The daily intake amount per body weight is not particularly limited, and can be appropriately set depending on the mode of use and the contents of use of the user. The intake amount per one time per body weight is also not particularly limited. When the pharmaceutical is an oral preparation, it may be taken, for example, before a meal, between meals, after a meal, or simultaneously with a meal.
[0034] When the pharmaceutical or quasi-drug of the composition of the present invention is an external preparation, its form may be, for example, lotion, milky lotion, gel, cream, ointment, powder, granule, etc. Specific examples include lotion, cosmetic cream, milky lotion, cream, pack, hair tonic, hair cream, shampoo, hair rinse, treatment, body shampoo, face wash, soap, foundation, face powder, lipstick, lip gloss, blush, eye shadow, hair styling agent, hair growth agent, aqueous ointment, oily ointment, eye drops, eye wash, poultice, gel, etc. The amount of use is not particularly limited, and can be appropriately selected in consideration of various factors such as the age, weight, constitution, and application site of the subject individual. The frequency of application to the subject is not particularly limited.
[0035] When the pharmaceutical or quasi-drug that is the composition of the present invention is an injection, it may be, for example, an aqueous suspension or oil suspension that can be prepared using a dispersing agent, a wetting agent, or / and a suspending agent. The injection may be in the form of a solution or suspension prepared using a solvent or diluent. As the solvent, for example, sterile water, Ringer's solution, or isotonic saline solution is used. The injection may be a powder that is reconstituted using an appropriate solution. The injection may contain, for example, a stabilizer, a pH regulator, or / and a surfactant as other components. The injection may be provided, for example, in the form of a unit dose ampoule or a multi-dose container. The dosage of the injection may be appropriately determined depending on, for example, its type and form, the age, sex, weight, and severity of symptoms of the subject. In addition, the injection may be administered once or in several doses per day within the desired dosage range, and may be administered before, between, after, or simultaneously with a meal.
[0036] The anti-glycation agent of the present invention may contain other components. The other components can be arbitrarily selected depending on the application, for example. Examples of the other components include solvents such as water and organic solvents, excipients, binders, gloss agents, lubricants, stabilizers, thickeners, emulsifiers, antioxidants, pH adjusters, colorants, flavors, sweeteners, acidulants, and / or additives.
[0037] Examples of the water include purified water, hot water, ion-exchanged water, etc. The water may be tap water or the like that has been subjected to a specific treatment, and examples of the specific treatment include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, etc.
[0038] The organic solvent may be at least one selected from the group consisting of alcohols (e.g., methanol, ethanol, propanol, etc.), esters (e.g., methyl acetate, ethyl acetate, etc.), alkanes (e.g., pentane, hexane, heptane, etc.), and halogenated alkanes (e.g., chloromethane, chloroethane, chloroform, or methylene chloride, etc.).
[0039] The excipient may be, for example, at least one selected from the group consisting of lactose hydrate, crystalline cellulose, corn starch, mannitol, and potato starch.
[0040] The binder may be, for example, at least one selected from the group consisting of microcrystalline cellulose, hypromellose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, povidone, low-substituted hydroxypropyl cellulose, and corn starch.
[0041] The polishing agent may be, for example, at least one selected from the group consisting of shellac, paraffin wax, and beeswax.
[0042] The lubricant may be, for example, at least one selected from the group consisting of magnesium stearate, talc, calcium stearate, stearic acid, sodium lauryl sulfate, and carnauba wax.
[0043] The stabilizer and thickener may be, for example, at least one selected from the group consisting of carrageenan, sodium carboxymethylcellulose, xanthan gum, guar gum, and pectin.
[0044] The emulsifier may be, for example, at least one selected from the group consisting of glycerin fatty acid esters, saponin, sucrose fatty acid esters, and lecithin.
[0045] The antioxidant may be, for example, at least one selected from the group consisting of L-ascorbic acid, erythorbic acid, catechin, dibutylhydroxytoluene, tocopherol, and butylhydroxyanisole.
[0046] The pH adjuster may be, for example, at least one selected from the group consisting of baking soda, sodium bicarbonate, citric acid, lactic acid, and calcined alum.
[0047] The coloring agent may be, for example, at least one selected from the group consisting of annatto color, turmeric color, caramel color, carotene color, gardenia color, carminic acid color, edible tar color, copper chlorophyll, monascus color, and safflower color.
[0048] The flavoring may be, for example, a chemically synthesized flavoring or a flavoring derived from a natural product. The flavoring may be a mixture of the chemically synthesized flavoring and the flavoring derived from a natural product.
[0049] The sweetener may be, for example, at least one selected from the group consisting of aspartame, acesulfame potassium, licorice extract, xylitol, saccharin, stevia, and D-sorbitol.
[0050] The acidulant may be, for example, at least one selected from the group consisting of citric acid, L-tartaric acid, and lactic acid.
[0051] Examples of the additives include food additives, pharmaceutical additives, and additives for quasi-drugs other than those listed as the other components.
[0052] The anti-glycation agent of the present invention may be used, for example, in humans or non-human animals, such as mammals such as cows, pigs, horses, sheep, goats, donkeys, monkeys, dogs, cats, rabbits, mice, rats, hamsters, and guinea pigs, or nematodes.
[0053] The anti-glycation agent of the present invention may be, for example, an agent for suppressing a decrease in blood glucose level. The agent for suppressing a decrease in blood glucose level may include, for example, an agent containing glucose, a glucagon preparation, or the like.
[0054] The weight ratio (C / N) of the weight of the CyD (C) to the weight of the NMN (N) contained in the anti-glycation agent of the present invention is not particularly limited and can be set as appropriate, and is, for example, 0.01 or more, 0.1 or more, 1 or more, 1.5 or more, 2 or more, 2.5 or more, 2.7 or more, 2.8 or more, or 2.9 or more, and is, for example, 10,000 or less, 1,000 or less, 100 or less, 50 or less, 30 or less, 25 or less, 15 or less, 10 or less, 8 or less, 5 or less, 4 or less, 3.5 or less, or 3 or less.
[0055] [2. Additives] Next, additives for use in anti-glycation agents will be described. The additives are, for example, additives added to nicotinamide mononucleotide, and include cyclodextrin.
[0056] The NMN may be the same as the NMN described in the above-mentioned anti-glycation agent of the present invention, for example. The CyD may be the same as the CyD described in the above-mentioned anti-glycation agent of the present invention, for example.
[0057] The additive is, for example, a stabilizer for the NMN. The stabilization by the stabilizer refers to, for example, stabilization against heat treatment, medium- to long-term storage, and the like. The heat treatment temperature is, for example, 40 to 200°C, 60 to 150°C, or 80 to 100°C, and the heat treatment time is, for example, 1 to 180 minutes, 15 to 120 minutes, or 30 to 60 minutes. The medium- to long-term storage temperature is, for example, 20 to 85°C, 25 to 70°C, or 35 to 50°C, and the storage period is, for example, 3 hours to 2 months, 1 day to 1 month, or 3 days to 2 weeks.
[0058] The additive may contain other components. The other components may be, for example, the same as the other components described above in the anti-glycation agent of the present invention.
[0059] The additive may be added in any amount relative to the weight (N) of the NMN. For example, the weight ratio (C / N) of the weight (C) of the CyD to the weight (N) of the NMN may be 0.01 or more, 0.1 or more, 1 or more, 1.5 or more, 2 or more, 2.5 or more, 2.7 or more, 2.8 or more, or 2.9 or more, and may be added so that, for example, it is 10,000 or less, 1,000 or less, 100 or less, 50 or less, 30 or less, 25 or less, 15 or less, 10 or less, 8 or less, 5 or less, 4 or less, 3.5 or less, or 3 or less.
[0060] [3. Method for producing anti-glycation agent] Next, the method for producing the anti-glycation agent of the present invention will be described. As described above, the method for producing the anti-glycation agent of the present invention includes a mixing step of mixing cyclodextrin and nicotinamide mononucleotide. The method for producing the composition of the present invention further includes, for example, a mixing step of mixing water.
[0061] The NMN may be, for example, the same as the NMN described in the composition of the present invention. The CyD may be, for example, the same as the CyD described in the composition of the present invention. Furthermore, the water may be, for example, the same as the water described in the composition of the present invention.
[0062] The mixing step may be performed by hand or by a mixing device, which may be a commonly used mixing means such as a mixer or a propeller agitator.
[0063] The method for producing an anti-glycation agent of the present invention may further include a drying step. Examples of the drying step include hot air drying, reduced pressure drying, freeze drying, and natural drying.
[0064] In the production method of an anti-glycation agent of the present invention, for example, the weight ratio (C / N) of the weight of the CyD (C) to the weight of the NMN (N) is 0.01 or more, 0.1 or more, 1 or more, 1.5 or more, 2 or more, 2.5 or more, 2.7 or more, 2.8 or more, or 2.9 or more, and may be, for example, 10,000 or less, 1,000 or less, 100 or less, 50 or less, 30 or less, 25 or less, 15 or less, 10 or less, 8 or less, 5 or less, 4 or less, 3.5 or less, or 3 or less.
[0065] When the mixing step includes a step of mixing the water, the ratio ([C+N] / W) of the total ([C+N]) of the weight of CyD (C) and the weight of NMN (N) to the weight of water (W) is not particularly limited and can be set appropriately, for example, 0.001 or more, 0.005 or more, 0.01 or more, 0.05 or more, 0.1 or more, 0.5 or more, 1 or more, 2 or more, 3 or more, 4 or more, or 4.5 or more, and for example, 2000 or less, 1500 or less, 1200 or less, 1100 or less, 1000 or less, 500 or less, 200 or less, 100 or less, 50 or less, 20 or less, 10 or less, 6 or less, or 5 or less. In addition, in calculating the ratio, for example, when the volume of the water is 1 mL, the weight of the water (W) can be calculated assuming that it is 1 g. EXAMPLES
[0066] Next, the present invention will be described in more detail, but the present invention is not limited to the following examples.
[0067] In this embodiment, the residual rate of NMN was determined using HPLC as described below, but the method for determining the residual rate is not limited to this. For example, the residual rate may be determined using a device or method capable of quantitative analysis such as a mass spectrometer, a spectrophotometer, an X-ray analyzer, or an elemental analyzer.
[0068] (Preparation of anti-glycation agent) [Example 1] Purified water was further added to a mixture of β-NMN and α-CyD in a weight ratio (C / N) of 2.95 in a ratio ([C+N] / W) of 4.9375, and the mixture after mixing was dried under reduced pressure at room temperature for 24 hours. The NMN / CyD composition obtained by this process was mixed with purified water so that the NMN in the composition was 5 mM, and the anti-glycation agent of Example 1 was obtained.
[0069] [Example 2] Purified water was added to a mixture of β-NMN and α-CyD in a weight ratio (C / N) of 2.95 in a ratio ([C+N] / W) of 4.9375, and the mixture was dried under reduced pressure at room temperature for 24 hours to obtain an NMN / CyD composition. The obtained NMN / CyD composition was mixed with a commercially available nutritional drink A so that the NMN in the composition was 5 mM, and the anti-glycation agent of Example 2 was obtained.
[0070] [Comparative Example 1] The same procedure as in Example 1 was carried out except that β-NMN and α-CyD were not used, to obtain the agent of Comparative Example 1.
[0071] [Comparative Example 2] β-NMN was dissolved in purified water to prepare a concentration of 5 mM, and the agent of Comparative Example 2 was obtained.
[0072] (Evaluation of healthy life expectancy) Wild-type nematodes (N2 nematodes) were reared in a medium containing 100 mM glucose for 4 days, and either of the anti-glycation agents or agents of Examples 1-2 or Comparative Examples 1-2 was administered to evaluate the quality of healthy lifespan. The quality of healthy lifespan was evaluated using the "qHaS (Healthable Score)" index of health impact by C-HAS Plus Co., Ltd., on a four-stage scale: (1) short lifespan, (2) unhealthy lifespan, (3) normal lifespan, and (4) healthy longevity. The evaluation results are shown in Figures 1 and 2.
[0073] FIG. 1 is a graph showing the health impact index (qHaS) per anti-glycation agent or agents administered.
[0074] As shown in FIG. 1, the proportion of healthy longevity in those using the agents of Comparative Examples 1 and 2 was 18.75% in Comparative Example 1 and 42.9% in Comparative Example 2. On the other hand, the proportion of healthy longevity in those using the anti-glycation agents of Examples 1 and 2 was 93.75% in Example 1 and 80.0% in Example 2. In other words, the proportion of healthy longevity in those using the anti-glycation agents of Examples 1 and 2 was higher than that in Comparative Examples 1 and 2. In particular, compared to Comparative Example 2 containing only NMN, the proportion of healthy lifespan in those using the anti-glycation agents of Examples 1 and 2 containing NMN and CyD was about twice as high. Furthermore, the proportion of unhealthy lifespan in those using the agents of Comparative Examples 1 and 2 was 12.5% in Comparative Example 1 and 7.1% in Comparative Example 2, and the proportion of short lifespan was 31.25% in Comparative Example 1 and 2 in Comparative Example 2. On the other hand, in the subjects using the anti-glycation agents of Examples 1 and 2, the proportion of unhealthy subjects was 0% in Example 1 and 6.7% in Example 2, and the proportion of short-lived subjects was 6.25% in Example 1 and 0% in Example 2. In other words, the subjects using the anti-glycation agents of Examples 1 and 2 had a lower proportion of unhealthy subjects and short-lived subjects compared to Comparative Examples 1 and 2. In particular, since the anti-glycation agents of Examples 1 and 2 contain NMN and CyD, the proportion of unhealthy subjects and short-lived subjects was lower than that of Comparative Example 2, which contains only NMN. In this way, the anti-glycation agents of Examples 1 and 2, which contain NMN and CyD, reduce the population of unhealthy subjects or short-lived subjects and increase the population of healthy subjects with long lifespans.
[0075] Figure 2 is a graph showing changes in healthy and unhealthy nematode populations. In Figures 2A and B, the vertical axis shows the percentage (%) and the horizontal axis shows the level.
[0076] 2A, the proportion of healthy nematode populations among all nematodes (proportion with qHaS evaluation of "standard" and "healthy longevity") was higher in the samples using the anti-glycation agents of Examples 1 and 2 compared to Comparative Examples 1 and 2. In particular, when compared to Comparative Example 2 containing only NMN, the proportion of healthy nematode populations among all nematodes in the samples using the anti-glycation agents of Examples 1 and 2 containing NMN and CyD increased by approximately 146% in Example 1 and approximately 145% in Example 2.
[0077] As shown in FIG. 2B, the proportion of unhealthy nematode populations (proportion of nematodes with qHaS evaluation of "unhealthy" and "short-lived") among all nematodes was lower in the cases where the anti-glycation agents of Examples 1 and 2 were used compared to Comparative Examples 1 and 2. In particular, when compared to Comparative Example 2 containing only NMN, the proportion of unhealthy nematode populations among all nematodes in the cases where the anti-glycation agents of Examples 1 and 2 containing NMN and CyD were used was reduced by approximately 82% in Example 1 and approximately 81% in Example 2. As shown in the results shown in FIG. 2A and FIG. 2B, the anti-glycation agents of Examples 1 and 2 containing NMN and CyD reduced the unhealthy population and increased the healthy population.
[0078] From the above, anti-glycation agents containing NMN and CyD qualitatively improve healthy lifespan under glucose loading conditions, i.e., they exhibit anti-glycation properties.
[0079] <Additional Notes> Some or all of the above embodiments may be described as follows, but are not limited to the following supplementary notes. (Appendix 1) Anti-glycation agents including cyclodextrin and nicotinamide mononucleotide. (Appendix 2) 2. The anti-glycation agent of claim 1, wherein the nicotinamide mononucleotide comprises β-nicotinamide mononucleotide. (Appendix 3) 3. The anti-glycation agent according to claim 1 or 2, wherein the cyclodextrin comprises α-cyclodextrin. (Appendix 4) 4. An anti-glycation agent according to any one of claims 1 to 3 for use in a liquid composition. (Appendix 5) 5. The anti-glycation agent according to any one of claims 1 to 4, for use in a beverage. (Appendix 6) 6. The anti-glycation agent according to any one of claims 1 to 5, which is an agent for suppressing a decrease in blood glucose level. (Appendix 7) mixing cyclodextrin and nicotinamide mononucleotide; A method for producing an anti-glycation agent according to any one of claims 1 to 6. [Industrial Applicability]
[0080] As described above, according to the present invention, it is possible to provide an anti-glycation agent having excellent anti-glycation activity and a method for producing an anti-glycation agent.
Claims
1. Anti-glycation agents including cyclodextrin and nicotinamide mononucleotide.
2. The anti-glycation agent according to claim 1 , wherein the nicotinamide mononucleotide comprises β-nicotinamide mononucleotide.
3. The anti-glycation agent according to claim 1 , wherein the cyclodextrin comprises α-cyclodextrin.
4. The anti-glycation agent according to claim 1 for use in a liquid composition.
5. The anti-glycation agent according to claim 1 for use in a beverage.
6. The anti-glycation agent according to claim 1 , which is an agent for suppressing a decrease in blood glucose level.
7. mixing cyclodextrin and nicotinamide mononucleotide; A method for producing the anti-glycation agent according to any one of claims 1 to 6.
Citation Information
Patent Citations
Natural killer cell activators
JP2018002604A
